Clinical trials: sponsored by UCB Biopharma SRL
Psoriatic Arthritis
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
- Trial name
- BE OPTIMAL (NCT03895203)
- Testing
- Bimekizumab, Adalimumab
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 852 people
- Sponsor
- UCB Biopharma SRL
Osteoporosis
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in…
- Trial name
- NCT05067335
- Testing
- Romosozumab
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- UCB Biopharma SRL
Atopic Dermatitis
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
- Trial name
- PossibILity (NCT07277660)
- Testing
- Galvokimig
- Where
- 59 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- NCT06921850
- Testing
- Bimekizumab
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR)…
- Trial name
- BE COMPLETE (NCT03896581)
- Testing
- Bimekizumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- UCB Biopharma SRL
Stereotypical Prolonged Seizures
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.
- Trial name
- NCT05076617
- Testing
- Staccato alprazolam
- Where
- 136 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- UCB Biopharma SRL
Nonradiographic Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis…
- Trial name
- BE MOBILE 1 (NCT03928704)
- Testing
- Bimekizumab
- Where
- 83 sites in United States, Belgium and 11 more
- Volunteers
- 274 people
- Sponsor
- UCB Biopharma SRL
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
- Trial name
- BE MOBILE 2 (NCT03928743)
- Testing
- Bimekizumab
- Where
- 83 sites in United States, Belgium and 12 more
- Volunteers
- 332 people
- Sponsor
- UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Trial name
- BE CARING (NCT06888193)
- Testing
- Bimekizumab
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to <18 years of age with moderate to severe…
- Trial name
- BE TOGETHER (NCT06425549)
- Testing
- bimekizumab, ustekinumab
- Where
- 42 sites in United States, Belgium and 8 more
- Volunteers
- 176 people
- Sponsor
- UCB Biopharma SRL
Healthy Participants
A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants
The purpose of the study is to evaluate the safety and tolerability of a single ascending dose of UCB3101 in cohorts of healthy male and female study participants.
- Trial name
- NCT06555601
- Testing
- UCB3101
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
- Trial name
- BE MOVING (NCT04436640)
- Testing
- Bimekizumab
- Where
- 75 sites in United States, Belgium and 12 more
- Volunteers
- 508 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
- Trial name
- BE VITAL (NCT04009499)
- Testing
- Bimekizumab
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 1,131 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
- Trial name
- NCT06624228
- Testing
- Bimekizumab, Risankizumab
- Where
- 127 sites in United States, Australia and 9 more
- Volunteers
- 553 people
- Sponsor
- UCB Biopharma SRL
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
- Trial name
- BeSeen (NCT07219420)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Canada and 11 more
- Volunteers
- 320 people
- Sponsor
- UCB Biopharma SRL
Healthy Participants
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.
- Trial name
- NCT06961747
- Testing
- Zilucoplan
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.
- Trial name
- NCT06315322
- Testing
- Brivaracetam Film-coated tablet, Brivaracetam oral solution
- Where
- 11 sites in United States, Georgia and 3 more
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma SRL
Generalized Myasthenia Gravis
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT04650854
- Testing
- Rozanolixizumab
- Where
- 69 sites in United States, Canada and 12 more
- Volunteers
- 165 people
- Sponsor
- UCB Biopharma SRL
Generalized Myasthenia Gravis
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).
- Trial name
- NCT03971422
- Testing
- Rozanolixizumab
- Where
- 112 sites in United States, Belgium and 15 more
- Volunteers
- 200 people
- Sponsor
- UCB Biopharma SRL
Generalized Myasthenia Gravis
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
- Trial name
- NCT04124965
- Testing
- Rozanolixizumab
- Where
- 43 sites in United States, Canada and 10 more
- Volunteers
- 71 people
- Sponsor
- UCB Biopharma SRL